<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The development of personalised therapy and mechanism-targeted agents in <z:hpo ids='HP_0002664'>oncology</z:hpo> mandates the identification of the patient populations most likely to benefit from therapy </plain></SENT>
<SENT sid="1" pm="."><plain>This paper discusses the increasing evidence as to the <z:hpo ids='HP_0001425'>heterogeneity</z:hpo> of the group of diseases called <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Differences in the aetiology and epidemiology of proximal and distal <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> are reflected in different clinical behaviour, histopathology, and molecular characteristics of these <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>This may impact response both to standard cytotoxic therapies and mechanism-targeted agents </plain></SENT>
<SENT sid="4" pm="."><plain>This disease <z:hpo ids='HP_0001425'>heterogeneity</z:hpo> leads to challenges in the design of clinical trials to assess novel therapies in the treatment of "<z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>." </plain></SENT>
</text></document>